Fortress Biotech, Inc. (FBIO)

NCM – Real Time Price. Currency in USD

2.26

+0.02 (0.89%)

At close: May 12, 2026, 4:00 PM EDT

2.25

-0.01 (-0.36%)

Pre-market: May 13, 2026, 5:46 AM EDT

06.05.2026

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET

04.05.2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, taking place on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 12:30pm ET.

21.04.2026

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026

31.03.2026

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium is also eligible to receive tiered royalties and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics

30.03.2026

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of the sale of Cyprium's Rare Pediatric Disease Priority Review Voucher (“PRV”) for gross proceeds of $205 million. “The sale of the PRV by Cyprium is a transformational corporate transaction for both Cyprium and Fortress.

25.03.2026

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz.

18.03.2026

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET

Videos

No Data

There is no data to display

Press releases

21.04.2026

Fortress Biotech, Inc. (FBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Fortress Biotech, Inc. (FBIO)

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Videos

No Data

Press releases

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Videos

No Data

Press releases

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Search stocks

Fortress Biotech, Inc. (FBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Fortress Biotech, Inc. (FBIO)

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Videos

No Data

Press releases

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Videos

No Data

Press releases

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights